Summary
IMvigor010 was a phase 3 multicentre randomised controlled trial comparing adjuvant atezolizumab (a PD-L1 checkpoint inhibitor) with observation in patients with high-risk muscle-invasive urothelial carcinoma following radical cystectomy. As suggested by the trial design, the study investigated whether perioperative immune checkpoint inhibition improves survival and disease-free survival outcomes in the adjuvant setting. This record falls outside Vitagri's core research remit on food systems, farming, soil health, and nutrient density.
UK applicability
This oncology trial has limited direct applicability to UK farming, food systems, or soil health research. However, findings on immunotherapy outcomes in cancer care may inform UK National Health Service clinical guidelines for bladder cancer management.
Key measures
Disease-free survival, overall survival, recurrence-free survival, adverse events
Outcomes reported
The study measured disease-free survival and overall survival in patients with high-risk muscle-invasive urothelial carcinoma receiving adjuvant atezolizumab versus observation post-radical cystectomy. Secondary outcomes included safety, tolerability, and recurrence-free survival.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.